In particular, sEVs from HCC were shown to induce sorafenib (TKI) resistance in vitro by activating hepatocyte growth factor/mesenchymal- epithelial transition factor/AKT (HGF/c-Met/Akt) signaling in other HCC cancer cells, thus preventing sorafenib-induced apoptosis [92]. This evidence concerns the gene MET and hepatocellular carcinoma.